Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder

International Clinical Psychopharmacology

Volumn 22, Issue 2, 2007, Pages 107-115

  Fantino, Bruno ^a   Moore, Nicholas ^b,c,d   Verdoux, Hélène ^d,e   Auray, Jean Paul ^f  

^a Association pour le Développement de l'Information Médicalisée   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INSERM U657   (France)

^e CENTRE HOSPITALIER CHARLES PERRENS   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Citalopram; Cost effectiveness; Escitalopram; Major depression; Randomized clinical trial

Indexed keywords

CITALOPRAM; ESCITALOPRAM;

ADULT; ARTICLE; BOOTSTRAPPING; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEMALE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CHARGE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL LEAVE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT CARE; PRIORITY JOURNAL; PSYCHIATRIST; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 33846964502     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3280128d16     Document Type: Article

References (34)

1. Ament A, Evers S, Baltussen R (2000). The usefulness of ratios for allocation decisions: the case of stroke. Cerebrovasc Dis 10:283-288.
2. Auquier P, Robitail S, Llorca PM, Rive B (2003). Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 7:259-268.
3. Azorin JM, Llorca PM, Despiegel N, Verpillat P (2004). Traitement des épisodes dépressifs sévères: escitalopram est plus efficace que citalopram. Encephale 30:158-166.
4. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336.
5. Colonna L, Reines EH, Andersen HF (2002). Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. (Poster presented at the 3rd International Forum on Mood and Anxiety Disorders (IFMAD); Monte Carlo, Monaco, 27-30 November 2002).
6. Committee for Proprietary Medicinal Products (2002). Note for guidance on clinical investigation of medicinal products in the treatment of depression. London: EMEA (CPMP/EWP/518/97, Rev. 1); 2002.
7. Croom KF, Plosker GL (2003). Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 21:1185-1209.
8. Croom KF, Plosker GL (2004). Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs 18:469-473.
9. Fernandez JL, Montgomery S, Francois C (2005). Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 23 (2):155-167.
10. Frank L, Revicki DA, Sorensen SV, Shih Y-CT (2001). The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 15:59-83.
11. Harlow SD, Linet MS (1989). Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am J Epidemiol 129:233-248.
12. Hemels ME, Kasper S, Walter E, Einarson TR (2004a). Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 20:869-878.
13. Hemels ME, Kasper S, Walter E, Einarson TR (2004b). Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 38:954-960.
14. Hyttel J, Bogeso KP, Perregaard J, Sanchez C (1992). The pharmacological effect of citalopram residues in the (S)-(+)- enantiomer. J Neural Transm Gen Sect 88:157-160.
15. Jonsson B, Bebbington PE (1994). What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 164:665-673.
16. Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, et al. (1995). Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 273:1026-1031.
17. Kienke AS, Rosenbaum JF (2000). Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety 12 (Suppl 1): 50-54.
18. Laukkala T, Isometsa E, Hamalainen J, Heikkinen M, Lindeman S, Aro H (2001). Antidepressant treatment of depression in the Finnish general population. Am J Psychiatry 158:2077-2079.
19. Lepola UM, Loft H, Reines EH (2003). Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211-217.
20. Llorca PM, Azorin JM, Despiegel N, Verpillat P (2005). Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59 (3):268-275.
21. Moore N, Verdoux H, Fantino B (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20 (3):131-137.
22. Mork A, Kreilgaard M, Sanchez C (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45:167-173.
23. Revicki DA, Irwin D, Reblando J, Simon GE (1994). The accuracy of self-reported disability days. Med Care 32:401-404.
24. Sanchez C (2003). R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur J Pharmacol 464:155-158.
25. Sanchez C, Kreilgaard M (2004). R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391-398.
26. Sanchez C, Gruca P, Bien E, Papp M (2003a). R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav 75:903-907.
27. Sanchez C, Gruca P, Papp M (2003b). R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14:465-470.
28. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174 (2):163-176.
29. Schatzberg AF (1996). Treatment of severe depression with the selective serotonin reuptake inhibitors. Depress Anxiety 4:182-189.
30. Schulberg HC, Block MR, Madonia MJ, Scott CP, Rodriguez E, Imber SD, et al. (1996). Treating major depression in primary care practice. Eight-month clinical outcomes. Arch Gen Psychiatry 53:913-919.
31. Stewart A (1998). Choosing an antidepressant: effectiveness based pharmacoeconomics. J Affect Disord 48:125-133.
32. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004). R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142:172-180.
33. Sugahara H, Akamine M, Kondo T, Fujisawa K, Yoshimasu K, Tokunaga S, Kubo C (2004). Somatic symptoms most often associated with depression in an urban hospital medical setting in Japan. Psychiatry Res 126:151-158.
34. Thase ME (2000). Treatment of severe depression. J Clin Psychiatry 61 (Suppl 1):17-25.